{"prompt": "['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '6.2', 'Product Complaint', '6.2.1', 'Definition', 'A Product Complaint is any Complaint (see Section 6.0 for the definition) related to the', 'biologic or drug component of the product.', 'For a product this may include, but is not limited to, damaged/broken product or', 'packaging, product appearance whose color/markings do not match the labeling, labeling', 'discrepancies/inadequacies in the labeling/instructions (example: printing illegible),', 'missing components/product, or packaging issues.', 'Any information available to help in the determination of causality to the events outlined', 'directly above should be captured.', '6.2.2', 'Reporting', 'Product Complaints concerning the investigational product must be reported to the', \"Sponsor within 24 hours of the study site's knowledge of the event via the Product\", 'Complaint eCRF. Product Complaints occurring during the study will be followed-up to a', 'satisfactory conclusion. All follow-up information is to be reported to the Sponsor (or an', 'authorized representative) and documented in source as required by the Sponsor. Product', 'Complaints associated with adverse events will be reported in the study summary. All', 'other complaints will be monitored on an ongoing basis.', 'Product Complaints may require return of the product with the alleged complaint', 'condition. In instances where a return is requested, every effort should be made by the', 'investigator to return the product within 30 days. If returns cannot be accommodated', 'within 30 days, the site will need to provide justification and an estimated date of return.', 'The description of the complaint is important for AbbVie in order to enable AbbVie to', 'investigate and determine if any corrective actions are required.', '92']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '7.0', 'Protocol Deviations', 'AbbVie does not allow intentional/prospective deviations from the protocol unless when', 'necessary to eliminate an immediate hazard to study subjects. The principal investigator', 'is responsible for complying with all protocol requirements, and applicable global and', 'local laws regarding protocol deviations. If a protocol deviation occurs (or is identified)', 'after a subject has been enrolled, the principal investigator is responsible for notifying', 'Independent Ethics Committee (IEC)/Independent Review Board (IRB) regulatory', 'authorities (as applicable), and the following AbbVie Clinical Monitor(s):', 'Primary Contact:', 'Alternate Contact:', 'Study Project Manager II', 'Study Project Manager I', 'AbbVie Corporation', 'AbbVie s.r.o.', '8401 Trans-Canada Highway', 'METRONOM BUSINESS CENTER', 'Saint-Laurent, Qu\u00e9bec', 'Bucharova 2817/13, Stodulky,', 'H4S 1Z1', '158 00 Praha 5', 'Canada', 'Czech Republic', 'Phone:', 'Phone:', 'Fax:', 'Fax:', 'Email:', 'Email:', 'Such contact must be made as soon as possible to permit a review by AbbVie to', 'determine the impact of the deviation on the subject and/or the study.', 'In Japan, the Investigator will record all protocol deviations in the appropriate medical', 'records at site.', '93']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', '8.0', 'Statistical Methods and Determination of Sample', 'Size', '8.1', 'Statistical and Analytical Plans', 'This section describes the planned statistical analyses to be performed using data captured', 'according to this protocol. A complete statistical analysis plan (SAP) describing in more', 'detail all planned analyses will be finalized prior to database lock.', 'The primary endpoints of OS and progress free survival (PFS) assessed by a Central', 'Radiographic Assessment Committee (CRAC) according to RECIST v1.1 in DLL3high', 'patients will be analyzed at the same time after observing at least 319 os events. It is', 'expected at approximately 420 PFS events will be observed at the time of the primary', 'analysis.', 'The following analysis sets are considered:', 'DLL3high Set: It includes all randomized subjects with DLL3 high ED SCLC.', 'Subjects will be classified according to the treatment arm to which they are', 'randomized regardless the actual treatment received, following intent-to-treat', 'principle. The DLL3high set will be the analysis set for the analysis of the', 'primary efficacy endpoints of os and PFS. All the exploratory efficacy', 'endpoints will be analyzed based on the DLL3 high set unless the OS and PFS', 'based on the randomized set are statistically significant.', 'Randomized Set: It includes all randomized subjects, with subjects grouped', 'according to the treatment arm to which they are randomized regardless the', 'actual treatment received, following intent-to-treat principle. The randomized', 'set will be the analysis set for key secondary efficacy endpoints of OS and', 'PFS, and key secondary endpoint of EORTC QLQ-C30 physical functioning', 'domain. All the exploratory efficacy endpoints will be analyzed based on the', 'randomization set if the OS and PFS based on the randomization set are', 'statistically significant.', 'Per Protocol Set: It includes all subjects in the randomized set without any', 'major protocol violations which may affect the evaluation of the primary', '94']\n\n###\n\n", "completion": "END"}